Zoetis has announced that it plans to launch Simparica Trio (sarolaner/moxidectin/pyrantel) chewable tablets, a once-monthly triple combination antiparasitic medication for dogs with, or at risk from, mixed external and internal parasitic infestations in spring 2020, now that it has gained the necessary EC marketing authorisation.

Simparica Trio contains sarolaner, which is active against fleas and ticks; moxidectin, effective against heartworm, lungworm and some intestinal worms; and pyrantel embonate, effective against gastrointestinal nematodes (hookworms and roundworms).

Dr. Domenico Otranto1, DVM, PhD, DipEVPC, Professor in Veterinary Parasitology at the University of Bari (Italy), said: "The approval of Simparica Trio provides veterinarians a safe and effective option for the treatment of mixed external and internal parasitic infestations in dogs in the form of a new oral chewable.

"Simparica Trio has been shown to rapidly kill fleas and ticks with concurrent efficacy for the prevention of heartworm disease and angiostrongylosis (lungworm disease) and treatment of intestinal round- and hookworms. The convenience of a once monthly chewable tablet helps increase compliance with treatment, giving veterinarians and dog owners confidence in continuous protection."

Dr. Catherine Knupp, Executive Vice President and President, Research and Development at Zoetis, said: "We are excited to bring Simparica Trio to veterinarians in the European Union as a new, effective triple combination parasiticide for dogs."


Whilst you're here, take a moment to see our latest job opportunities for vets.